4.7 Review

FGF Family: From Drug Development to Clinical Application

期刊

出版社

MDPI
DOI: 10.3390/ijms19071875

关键词

fibroblast growth factor; wound healing; metabolic regulation; fibroblast growth factor receptor inhibitor; drug development; clinical application

资金

  1. National Natural Science Foundation of China [81601695, 81600759]
  2. Natural Science Foundation of Zhejiang Province [LY17H150018, LY17H300012]
  3. science and technology project of Wenzhou [Y20150105]

向作者/读者索取更多资源

Fibroblast growth factor (FGF) belongs to a large family of growth factors. FGFs use paracrine or endocrine signaling to mediate a myriad of biological and pathophysiological process, including angiogenesis, wound healing, embryonic development, and metabolism regulation. FGF drugs for the treatment of burn and ulcer wounds are now available. The recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in maintaining homeostasis of bile acid, glucose, and phosphate further extended the activity profile of this family. Here, the applications of recombinant FGFs for the treatment of wounds, diabetes, hypophosphatemia, the development of FGF receptor inhibitors as anti-neoplastic drugs, and the achievements of basic research and applications of FGFs in China are reviewed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据